Abstract
BackgroundResection and replacement of the inferior vena cava to remove malignant disease is a formidable procedure. The purpose of this review is to describe our experience with regard to patient selection, operative technique, and early and late outcome.MethodsThe authors retrospectively reviewed a 12-year series of 11 patients; there were 10 males, with a mean age 57 ± 13 years (range 27–72) who underwent caval thrombectomy and/or resection for primary (n = 9) or recurrent (n = 2) vena cava tumours. Tumour location and type, clinical presentation, the segment of vena cava treated, graft patency, and tumour recurrence and survival data were collected. Late follow-up data were available for all patients. Graft patency was determined before hospital discharge and in follow-up by CT scan or ultrasonography. More than 80% of patients had symptoms from their caval involvement. The most common pathologic diagnosis was renal cell carcinoma (n = 6), and hepatocarcinoma (n = 2). In all but 2 patients, inferior vena cava surgical treatment was associated with multivisceral resection, including extended nephrectomy (n = 5), resection of neoplastic mass (n = 3), major hepatic resection (n = 2), and adrenal gland resection (n = 1). Prosthetic repair was performed in 5 patients (45%).ResultsThere were no early deaths. Major complications occurred in 1 patient (9%). Mean length of stay was 16 days. Late graft thrombosis or infection did not occur. The mean follow-up was 22.7 months (range 6–60). There have been no other late graft-related complications. All late deaths were caused by the progression of malignant disease and the actuarial survival rate was 100% at 1 year. Mean survival was 31 months (median 15).ConclusionAggressive surgical management may offer the only chance for cure or palliation for patients with primary or secondary caval tumours. Our experience confirms that vena cava surgery for tumours may be performed safely with low graft-related morbidity and good patency in carefully selected patients.
Highlights
Resection and replacement of the inferior vena cava to remove malignant disease is a formidable procedure
A variety of tumours were encountered; partial resection of the caval wall, with either primary or patch closure, has been reported to be preferable to graft replacement because it is safer and easier to perform [2]. The aim of this retrospective analysis is to describe the outcome of surgical treatment for inferior vena cava (IVC) malignant involvement in a series of 11 patients with extensive abdominal tumours and to discuss our policy for IVC replacement
IVC resection was associated with visceral resection, including extended nephrectomy (n = 5), resection of retroperitoneal mass (n = 3), major hepatic resection (n = 2), and excision of the adrenal gland (n = 1)
Summary
Resection and replacement of the inferior vena cava to remove malignant disease is a formidable procedure. Resection and replacement for malignant involvement of the inferior vena cava (IVC) is generally indicative of advanced disease, and has been performed rarely because of the magnitude and risk of the operation; in the absence of surgical resection, patient survival is limited, because effective treatment alternatives are few [2]. A variety of tumours were encountered; partial resection of the caval wall, with either primary or patch closure, has been reported to be preferable to graft replacement because it is safer and easier to perform [2] The aim of this retrospective analysis is to describe the outcome of surgical treatment for IVC malignant involvement in a series of 11 patients with extensive abdominal tumours and to discuss our policy for IVC replacement
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
